MarketCapExport financials
Accuray Incorporated (ARAY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Accuray Incorporated Financial Ratios 2026-2009 | ARAY
Brief overview of Accuray Incorporated's market valuation
The comparison uses the five latest available annual observations between 2021 and 2025.
The valuation comparison uses EV/EBITDA 35.17x (median 38.52x), P/S 0.35x (median 0.45x), P/B 1.98x (median 4.14x). The current ratio basket stands about 15.8% below the five-year comparison base. Earnings and risk trends should explain the discount.
End-period return metrics are ROE -2%, ROA -0.3%, ROCE 9.7%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
PEG of 0.12x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
A shorter cycle, from 248.8 days to 184.1 days, indicates faster release of cash from operations.
Overall assessment
Accuray Incorporated's valuation is lower, but weak quality metrics call for caution. Recovery in earnings and capital returns is the key catalyst.
Annual Financial Ratios Accuray Incorporated
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.6 | -100.8 | -12.0 | -27.3 | -36.5 | -53.2 | 93.9 | -21.9 | -13.3 | -11.9 | -17.3 | -12.6 | -17.6 | -4.4 | -6.3 | -15.5 | 86.1 | - |
P/S |
0.1 | 0.3 | 0.4 | 0.6 | 0.5 | 0.8 | 0.9 | 0.9 | 0.8 | 0.9 | 1.1 | 1.3 | 1.7 | 1.4 | 1.1 | 1.9 | - | - |
EPS |
-0.4 | -0.0 | -0.2 | -0.1 | -0.1 | -0.1 | 0.0 | -0.2 | -0.3 | -0.4 | -0.3 | -0.5 | -0.5 | -1.4 | -1.0 | -0.4 | 0.1 | - |
EV (Enterprise Value) |
393 M | 492 M | 542 M | 589 M | 526 M | 629 M | 677 M | 671 M | 565 M | 638 M | 731 M | 821 M | 928 M | 745 M | 580 M | 534 M | 307 M | -36.8 M |
EBITDA per Share |
-0.15 | 0.14 | 0.07 | 0.07 | 0.15 | 0.31 | 0.22 | 0.127 | 0.0699 | 0.0996 | 0.167 | 0.00414 | 0.0319 | -0.752 | -0.429 | -0.345 | 0.17 | - |
EV/EBITDA |
-21.3 | 35.2 | 84.5 | 85.3 | 38.5 | 19.9 | 14.2 | 40.0 | 61.7 | 53.9 | 39.6 | 1943.7 | 300.5 | -10.4 | -12.8 | -15.4 | 30.9 | - |
PEG |
0.02 | -14.01 | -6.18 | -1.5 | -1.6 | -2.12 | 0.12 | -0.68 | -0.6 | 0.95 | -0.46 | 1.48 | -0.26 | 0.11 | 0.05 | 0.02 | - | - |
P/B |
0.8 | 2.0 | 4.1 | 4.7 | 3.7 | 4.9 | 5.6 | 7.2 | 6.5 | 7.5 | 7.4 | 6.7 | 6.3 | 4.2 | 2.2 | 1.7 | - | - |
P/CF |
-4.6 | 56.1 | -15.7 | 16.3 | -81.4 | 8.7 | -244.7 | -10.6 | 27.2 | -61.0 | 17.3 | -18.6 | -53.9 | -5.5 | -9.3 | 49.5 | - | - |
ROE % |
-117.97 | -1.96 | -34.48 | -17.29 | -10.05 | -9.17 | 6.01 | -32.94 | -49.14 | -63.57 | -42.75 | -53.06 | -35.97 | -96.62 | -35.34 | -11.10 | 2.41 | - |
ROA % |
-11.09 | -0.34 | -3.32 | -1.94 | -1.13 | -1.31 | 0.78 | -3.75 | -6.31 | -7.28 | -5.44 | -8.56 | -7.16 | -21.69 | -15.23 | -5.85 | - | - |
ROCE % |
-63.41 | 9.66 | 1.12 | 4.44 | 15.32 | 32.30 | 19.70 | 0.24 | -1.81 | -8.05 | -1.88 | -6.39 | -5.84 | -25.20 | -21.07 | -11.19 | 1.67 | - |
Current Ratio |
1.1 | 1.2 | 1.1 | 1.1 | 1.1 | 1.2 | 1.1 | 1.8 | 1.7 | 1.1 | 1.7 | 2.1 | 2.0 | 2.2 | 1.8 | 1.4 | - | - |
DSO |
68.4 | 69.7 | 68.2 | 69.0 | 76.3 | 81.0 | 96.5 | 97.5 | 59.5 | 69.3 | 52.0 | 74.7 | 71.3 | 64.1 | 60.6 | 101.6 | - | - |
DIO |
181.0 | 163.6 | 170.4 | 178.6 | 181.3 | 200.6 | 199.7 | 172.2 | 162.9 | 158.4 | 176.3 | 165.3 | 141.3 | 136.4 | 109.6 | 310.4 | - | - |
DPO |
46.9 | 49.2 | 50.3 | 40.4 | 34.3 | 32.8 | 41.2 | 42.1 | 29.6 | 26.4 | 23.2 | 20.4 | 25.2 | 26.6 | 24.4 | 122.6 | - | - |
Operating Cycle |
249.4 | 233.4 | 238.6 | 247.6 | 257.6 | 281.7 | 296.2 | 269.7 | 222.4 | 227.7 | 228.3 | 240.0 | 212.6 | 200.5 | 170.2 | 412.0 | - | - |
Cash Conversion Cycle |
202.5 | 184.1 | 188.2 | 207.2 | 223.3 | 248.8 | 255.0 | 227.6 | 192.8 | 201.3 | 205.2 | 219.6 | 187.4 | 173.8 | 145.8 | 289.4 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Accuray Incorporated
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | -0.09 | -0.11 | -0.18 | -0.11 | -0.18 | - | -0.01 | 0.03 | -0.04 | - | -0.06 | -0.1 | -0.03 | - | 0.01 | -0.02 | -0.06 | -0.08 | -0.01 | - | -0.01 | -0.01 | - | 0.05 | - | 0.05 | - | 0.12 | -0.11 | 0.12 | -0.01 | -0.05 | -0.11 | -0.05 | -0.11 | -0.06 | -0.11 | -0.06 | -0.06 | -0.11 | 0.01 | -0.09 | 0.01 | -0.08 | -0.16 | -0.08 | -0.04 | -0.13 | -0.28 | -0.13 | -0.28 | -0.07 | -0.21 | -0.07 | -0.21 | -0.4 | -0.34 | -0.28 | -0.21 | -0.15 | -0.38 | -0.15 | -0.02 |
EBITDA per Share |
- | -25.5 | -63.9 | -81 | -80.7 | -0.08 | - | - | 61.2 | -0.01 | - | - | - | 0.04 | - | - | 0.03 | -0.01 | 0.03 | - | 0.04 | 0.04 | 0.1 | 0.05 | 0.09 | 0.08 | 0.13 | 0.08 | 0.04 | -0.03 | 0.08 | -0.03 | -0.01 | -0.03 | 0.04 | -0.03 | -0.01 | 0.01 | 0.05 | 0.01 | -0.03 | -0.02 | 0.05 | -0.02 | 0.02 | -0.03 | 0.11 | -0.03 | -0.02 | -0.13 | 0.08 | -0.13 | 0.02 | -0.09 | 0.13 | -0.09 | -0.28 | -0.18 | -0.11 | -0.38 | -0.02 | -0.23 | 0.13 | -0.23 |
ROE % |
-89.12 | -114.90 | -121.63 | -98.47 | -58.13 | -41.10 | -6.06 | -21.50 | -39.07 | -50.20 | -41.46 | -40.36 | -28.54 | -19.95 | -14.12 | -27.89 | -31.01 | -27.04 | -17.69 | -5.16 | -5.37 | 0.41 | 8.78 | 16.15 | 18.99 | 31.98 | 44.98 | 57.97 | 34.54 | 5.36 | -23.82 | -53.00 | -49.71 | -49.26 | -58.49 | -59.14 | -49.93 | -60.41 | -59.72 | -81.36 | -87.66 | -77.48 | -79.19 | -54.24 | -41.52 | -44.77 | -51.36 | -53.92 | -54.87 | -47.44 | -36.95 | -44.51 | -68.85 | -82.47 | -80.02 | -72.44 | -61.75 | -47.05 | -44.62 | -39.75 | -33.45 | -11.52 | -5.07 | -12.22 |
ROA % |
-10.46 | -13.53 | -15.64 | -12.83 | -7.56 | -5.32 | -0.57 | -1.94 | -3.70 | -4.85 | -4.01 | -3.89 | -2.92 | -2.06 | -1.44 | -2.99 | -3.34 | -2.90 | -1.95 | -0.58 | -0.57 | 0.39 | 1.63 | 2.78 | 3.08 | 4.31 | 5.60 | 7.07 | 4.85 | 1.42 | -2.15 | -5.82 | -6.11 | -6.05 | -7.18 | -7.25 | -6.05 | -7.17 | -7.13 | -9.96 | -10.83 | -9.85 | -10.32 | -7.41 | -5.93 | -6.79 | -8.68 | -9.46 | -9.77 | -8.75 | -7.33 | -9.28 | -14.89 | -20.79 | -23.02 | -23.37 | -24.47 | -19.56 | -19.35 | -17.75 | -16.25 | -5.30 | -2.67 | -6.16 |
ROCE % |
-61.72 | -83.38 | -79.87 | -56.11 | -28.00 | -11.10 | 7.19 | -3.92 | -14.35 | -19.83 | -15.08 | -10.85 | 5.49 | 9.16 | 4.82 | 5.80 | 1.00 | 3.58 | 13.49 | 21.79 | 32.03 | 34.77 | 36.53 | 37.78 | 36.22 | 32.15 | 17.48 | 13.40 | -5.15 | -13.50 | -16.02 | -24.37 | -23.87 | -24.06 | -18.12 | -18.31 | -12.58 | -20.85 | -28.89 | -34.91 | -41.66 | -31.53 | -30.54 | -22.62 | -21.18 | -25.71 | -33.41 | -36.89 | -43.28 | -39.31 | -33.31 | -30.34 | -25.90 | -39.91 | -38.86 | -49.11 | -55.45 | -43.12 | -41.92 | -34.04 | -26.95 | -10.73 | -3.04 | -10.74 |
Current Ratio |
1.2 | 1.1 | 1.1 | 1.2 | 1.1 | 1.2 | 1.2 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.1 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.2 | 1.3 | 1.3 | 1.6 | 1.6 | 1.8 | 1.8 | 1.9 | 1.9 | 2.1 | 2.1 |
DSO |
- | 54.6 | 51.5 | 56.0 | 51.5 | 66.8 | - | 66.7 | 70.3 | 82.6 | - | 67.9 | 65.8 | 66.8 | - | 64.4 | 66.1 | 81.1 | 39.7 | 81.2 | 69.0 | 76.2 | 34.8 | 67.0 | 65.7 | 88.6 | 84.8 | 95.3 | 88.8 | 110.3 | 97.7 | 94.8 | 68.1 | 63.0 | 52.9 | 67.1 | 68.5 | 71.5 | 34.7 | 67.7 | 67.1 | 60.0 | 59.2 | 64.8 | 51.4 | 68.4 | 65.1 | 71.6 | 53.9 | 69.3 | 67.1 | 80.8 | 65.2 | 68.8 | 54.0 | 70.8 | 71.0 | 69.2 | 79.7 | 78.2 | 65.1 | 63.5 | 53.0 | - |
DIO |
- | 176.4 | 178.9 | 207.5 | 178.9 | 200.7 | - | 165.1 | 186.5 | 199.4 | - | 199.3 | 195.2 | 209.1 | - | 176.1 | 195.9 | 217.4 | 95.5 | 194.1 | 155.0 | 169.6 | 81.2 | 191.6 | 225.3 | 251.7 | 216.5 | 242.7 | 195.1 | 201.4 | 181.0 | 193.6 | 169.2 | 178.1 | 154.9 | 175.1 | 170.0 | 188.6 | 157.2 | 191.6 | 190.5 | 193.0 | 188.6 | 188.2 | 154.9 | 180.1 | 146.0 | 172.4 | 156.4 | 156.9 | 134.2 | 147.0 | 144.9 | 154.2 | 134.2 | 155.0 | 152.1 | 126.2 | 145.7 | 127.1 | 114.6 | 108.7 | 134.9 | - |
DPO |
- | 55.2 | 50.1 | 58.2 | 50.1 | 51.7 | - | 56.1 | 63.8 | 67.9 | - | 52.9 | 47.4 | 48.6 | - | 35.9 | 42.5 | 47.4 | 21.7 | 45.8 | 32.1 | 28.2 | 12.6 | 22.0 | 23.1 | 37.4 | 37.3 | 41.3 | 34.2 | 42.8 | 44.3 | 49.1 | 40.9 | 35.9 | 28.1 | 35.9 | 36.0 | 34.3 | 26.2 | 36.8 | 34.3 | 26.7 | 24.8 | 28.8 | 22.8 | 21.9 | 18.0 | 23.8 | 23.5 | 25.4 | 23.9 | 25.7 | 27.4 | 31.0 | 26.2 | 33.3 | 43.4 | 35.7 | 32.5 | 31.1 | 32.2 | 38.0 | 53.3 | - |
Operating Cycle |
- | - | - | - | 230.3 | 267.6 | - | 231.7 | 256.9 | 282.0 | - | 267.2 | 261.1 | 275.9 | - | 240.5 | 262.0 | 298.4 | 135.2 | 275.4 | 224.0 | 245.8 | 116.0 | 258.6 | 291.1 | 340.2 | 301.4 | 338.1 | 283.9 | 311.8 | 278.7 | 288.4 | 237.4 | 241.2 | 207.8 | 242.2 | 238.5 | 260.1 | 191.9 | 259.4 | 257.5 | 253.0 | 247.8 | 253.0 | 206.3 | 248.4 | 211.1 | 244.1 | 210.2 | 226.2 | 201.3 | 227.9 | 210.2 | 223.1 | 188.3 | 225.8 | 223.2 | 195.4 | 225.4 | 205.3 | 179.7 | 172.2 | 187.9 | - |
Cash Conversion Cycle |
- | - | - | - | 180.2 | 215.8 | - | 175.7 | 193.1 | 214.1 | - | 214.3 | 213.7 | 227.3 | - | 204.5 | 219.5 | 251.1 | 113.4 | 229.6 | 191.9 | 217.5 | 103.4 | 236.6 | 267.9 | 302.8 | 264.1 | 296.8 | 249.7 | 268.9 | 234.4 | 239.3 | 196.5 | 205.2 | 179.7 | 206.3 | 202.5 | 225.8 | 165.8 | 222.6 | 223.2 | 226.3 | 223.1 | 224.2 | 183.5 | 226.6 | 193.1 | 220.3 | 186.8 | 200.9 | 177.4 | 202.2 | 182.8 | 192.1 | 162.1 | 192.5 | 179.7 | 159.7 | 192.9 | 174.2 | 147.4 | 134.2 | 134.7 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Accuray Incorporated, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
$ 43.32 | 0.04 % | $ 1.99 B |  USA |
 |
Bruker Corporation
BRKR
|
$ 59.67 | 0.18 % | $ 9.06 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.73 | 1.16 % | $ 637 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 14.97 | 13.03 % | $ 424 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
CONMED Corporation
CNMD
|
$ 45.8 | 3.31 % | $ 1.42 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 4.91 | 0.75 % | $ 306 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.96 | 1.8 % | $ 572 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.7 | 0.43 % | $ 770 M | USA |
 |
Electromed
ELMD
|
$ 27.57 | 0.11 % | $ 228 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 67.76 | 3.69 % | $ 2.01 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.82 | 0.51 % | $ 50.8 B | USA |
 |
Align Technology
ALGN
|
$ 148.17 | 4.36 % | $ 10.7 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.88 | 2.45 % | $ 63.5 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 15.53 | 2.76 % | $ 1.19 B | USA |
 |
Inogen
INGN
|
$ 5.09 | 2.55 % | $ 135 M | USA |
 |
Inspire Medical Systems
INSP
|
$ 69.06 | 0.57 % | $ 2.03 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 0.08 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.35 | 0.08 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.32 | 0.02 % | $ 4.39 B | USA |
|
LENSAR
LNSR
|
$ 7.15 | 0.14 % | $ 85.5 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Apyx Medical Corporation
APYX
|
$ 2.95 | 1.37 % | $ 121 M | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Medtronic PLC
MDT
|
$ 89.3 | 0.08 % | $ 114 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.77 | 0.2 % | $ 705 M | USA |
 |
Myomo
MYO
|
$ 1.64 | 0.3 % | $ 68.6 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.7 | 0.45 % | $ 45.4 M | Israel |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M |  Britain |
 |
InspireMD
NSPR
|
$ 0.74 | 0.16 % | $ 47.6 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.18 | 2.23 % | $ 364 M |  Curacao |
 |
Outset Medical
OM
|
$ 3.09 | 5.45 % | $ 47 K | USA |
 |
Boston Scientific Corporation
BSX
|
$ 44.62 | 0.31 % | $ 66.1 B | USA |
 |
Insulet Corporation
PODD
|
$ 136.49 | 0.01 % | $ 9.6 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.74 | 0.16 % | $ 174 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.16 | 4.93 % | $ 135 M | USA |
 |
AVITA Medical
RCEL
|
$ 10.95 | 0.61 % | $ 305 M |  Australia |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Sintx Technologies
SINT
|
$ 1.78 | 3.98 % | $ 4.94 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.82 | 0.07 % | $ 23.3 B | Britain |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |
 |
Sensus Healthcare
SRTS
|
$ 3.03 | 0.32 % | $ 49.5 M | USA |
 |
Stryker Corporation
SYK
|
$ 273.4 | 0.38 % | $ 104 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.43 | 0.55 % | $ 513 M | USA |
 |
TELA Bio
TELA
|
$ 1.3 | 0.71 % | $ 61 M | USA |
 |
Viemed Healthcare
VMD
|
$ 8.8 | 1.24 % | $ 342 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |